Lbp Am Sa Buys 52,303 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

LBP AM SA lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 20.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,221 shares of the company's stock after purchasing an additional 52,303 shares during the quarter. LBP AM SA owned about 0.13% of BioNTech worth $27,793,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its position in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after acquiring an additional 1,401,547 shares in the last quarter. Bank of New York Mellon Corp lifted its position in BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after acquiring an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets bought a new position in BioNTech in the 4th quarter valued at approximately $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in BioNTech by 632.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Finally, Capital International Investors lifted its position in BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on BNTX. The Goldman Sachs Group began coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the company an "overweight" rating in a research note on Thursday. Truist Financial reiterated a "buy" rating and set a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and set a $138.00 target price on shares of BioNTech in a research note on Wednesday, June 25th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, BioNTech has an average rating of "Moderate Buy" and a consensus target price of $137.91.

BioNTech Price Performance

BioNTech stock traded down $1.03 during mid-day trading on Friday, hitting $112.89. The stock had a trading volume of 521,908 shares, compared to its average volume of 943,160. The firm has a market capitalization of $27.14 billion, a P/E ratio of -33.20 and a beta of 1.29. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The firm's 50 day moving average is $103.56 and its 200 day moving average is $106.86. BioNTech SE Sponsored ADR has a one year low of $76.53 and a one year high of $131.49.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.